Jump to content
Wikipedia The Free Encyclopedia

Meclofenamic acid

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Meclofenamic acid
Clinical data
Trade names Meclomen
AHFS/Drugs.com International Drug Names
Routes of
administration
By mouth
ATC code
Identifiers
  • 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.010.382 Edit this at Wikidata
Chemical and physical data
Formula C14H11Cl2NO2
Molar mass 296.15 g·mol−1

Meclofenamic acid (used as meclofenamate sodium, brand name Meclomen) is a drug used for joint, muscular pain, arthritis and dysmenorrhea.[1] It is a member of the anthranilic acid derivatives (or fenamate) class of nonsteroidal anti-inflammatory drugs (NSAIDs) and was approved by the US FDA in 1980.[2] Like other members of the class, it is a cyclooxygenase (COX) inhibitor, preventing the formation of prostaglandins.[3]

Scientists led by Claude Winder from Parke-Davis invented meclofenamate sodium in 1964, along with fellow members of the class, mefenamic acid in 1961 and flufenamic acid in 1963.[4] : 718 

Patents on the drug expired in 1985[5] : 295  and several generics were introduced in the US, but as of July 2015 only Mylan still sold it.[6] [7]

It is not widely used in humans as it has a high rate (30-60%) rate of gastrointestinal side effects.[8] : 310 

Adverse effects

[edit ]

In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[9] [10] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[9] [10]

Use in horses

[edit ]

Meclofenamic acid is sold under the trade name "Arquel" for use in horses, and is administered as an oral granule form at a dose of 2.2 mg/kg/day.[11] It has a relatively slow onset of action, taking 36–48 hours for full effect,[12] and is most useful for treatment of chronic musculoskeletal disease.[13] It has been found to be beneficial for the treatment of navicular syndrome, laminitis, and osteoarthritis,[12] in some cases having a more profound effect than the commonly used NSAID phenylbutazone.[14] However, due to cost, it is not routinely used in practice. Toxicity due to excessive dosage is similar to that of phenylbutazone, including depression, anorexia, weight loss, edema, diarrhea, oral ulceration, and decreased hematocrit.[14]

References

[edit ]
  1. ^ "meclofenamate, Meclomen: Drug Facts, Side Effects and Dosing". medicinenet.com.
  2. ^ FDA Meclomen page at FDA Page accessed July 3, 2015
  3. ^ "Mefenamic Acid". NIH LiverTox Database. June 23, 2015. PMID 31643176 . Retrieved July 3, 2015.
  4. ^ Whitehouse M (2009). "Drugs to Treat Inflammation: A Historical Overview.". In Rahman A, et al. (eds.). Frontiers in Medicinal Chemistry. Vol. 4. Bentham Science Publishers. pp. 707–729. ISBN 978-1-60805-207-3.
  5. ^ United States. Congress. Office of Technology Assessment Pharmaceutical R & D: Costs, Risks & Rewards DIANE Publishing, 1993 ISBN 978-0-7881-0468-8
  6. ^ "Meclofenamate sodium ANDAs". U.S. Food and Drug Administration. Archived from the original on 4 June 2015. Retrieved 3 July 2015.
  7. ^ "Mylan label for meclofenamate sodium". Daily Med. U.S. Food and Drug Administration. October 2013. Retrieved 3 July 2015.
  8. ^ Aronson JK (2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. ISBN 978-0-08-093294-1.
  9. ^ a b "FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  10. ^ a b "NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration. 21 July 2017. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ McIlwraith CW, Frisbie DD, Kawcak CE (2001). "Nonsteroidal Anti-Inflammatory Drugs". Proc. AAEP. 47: 182–187.
  12. ^ a b Cotter GH, Riley WF, Beck CC, Coppock RW (1973). "Arquel (Cl- 1583). A new nonsteroidal anti-inflammatory drug for horses". Proceedings. Am Assoc Equine Practnr. 19: 81–90.
  13. ^ Snow DH, Baxter P, Whiting B (June 1981). "The pharmacokinetics of meclofenamic acid in the horse". Journal of Veterinary Pharmacology and Therapeutics. 4 (2): 147–56. doi:10.1111/j.1365-2885.1981.tb00724.x. PMID 7349327.
  14. ^ a b Lees P, Higgins AJ (March 1985). "Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse". Equine Veterinary Journal. 17 (2): 83–96. doi:10.1111/j.2042-3306.1985.tb02056.x. PMID 3987667.
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones /
pyrazolidines
salicylates
acetic acid derivatives
and related substances
oxicams
propionic acid
derivatives (profens)
n-arylanthranilic
acids (fenamates)
COX-2 inhibitors
(coxibs)
other
NSAID
combinations
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; withdrawn drugs; veterinary use.
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
Receptor
(ligands)
DP (D2) Tooltip Prostaglandin D2 receptor
DP1 Tooltip Prostaglandin D2 receptor 1
DP2 Tooltip Prostaglandin D2 receptor 2
EP (E2) Tooltip Prostaglandin E2 receptor
EP1 Tooltip Prostaglandin EP1 receptor
EP2 Tooltip Prostaglandin EP2 receptor
EP3 Tooltip Prostaglandin EP3 receptor
EP4 Tooltip Prostaglandin EP4 receptor
Unsorted
FP (F) Tooltip Prostaglandin F receptor
IP (I2) Tooltip Prostacyclin receptor
TP (TXA2) Tooltip Thromboxane receptor
Unsorted
Enzyme
(inhibitors)
COX
(PTGS)
PGD2S Tooltip Prostaglandin D synthase
PGES Tooltip Prostaglandin E synthase
PGFS Tooltip Prostaglandin F synthase
PGI2S Tooltip Prostacyclin synthase
TXAS Tooltip Thromboxane A synthase
Others
Receptor
(ligands)
BLT Tooltip Leukotriene B4 receptor
BLT1 Tooltip Leukotriene B4 receptor 1
BLT2 Tooltip Leukotriene B4 receptor 2
CysLT Tooltip Cysteinyl leukotriene receptor
CysLT1 Tooltip Cysteinyl leukotriene receptor 1
CysLT2 Tooltip Cysteinyl leukotriene receptor 2
CysLTE Tooltip Cysteinyl leukotriene receptor E
Enzyme
(inhibitors)
5-LOX Tooltip Arachidonate 5-lipoxygenase
12-LOX Tooltip Arachidonate 12-lipoxygenase
15-LOX Tooltip Arachidonate 15-lipoxygenase
LTA4H Tooltip Leukotriene A4 hydrolase
LTB4H Tooltip Leukotriene B4 ω-hydroxylase
LTC4S Tooltip Leukotriene C4 synthase
LTC4H Tooltip Leukotriene C4 hydrolase
LTD4 Tooltip Leukotriene D4 hydrolase
Others
Calcium
VDCCs Tooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCs Tooltip Voltage-gated potassium channels
Blockers
Activators
IRKs Tooltip Inwardly rectifying potassium channel
Blockers
Activators
KCa Tooltip Calcium-activated potassium channel
Blockers
Activators
K2Ps Tooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCs Tooltip Voltage-gated sodium channels
Blockers
Activators
ENaC Tooltip Epithelial sodium channel
Blockers
Activators
ASICs Tooltip Acid-sensing ion channel
Blockers
Chloride
CaCCs Tooltip Calcium-activated chloride channel
Blockers
Activators
CFTR Tooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPs Tooltip Transient receptor potential channels
LGICs Tooltip Ligand gated ion channels

AltStyle によって変換されたページ (->オリジナル) /